Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from NetworkNewsWire, examining how, despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers.

Predictive Oncology (POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Predictive Oncology (POAI), closed Wednesday's trading session at $4.66, up 3.9529%, on 160,600 volume with 837 trades. The average volume for the last 3 months is 9,909 and the stock's 52-week low/high is $3.31999993/$8.50.

Recent News

• Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
• New Hope in the Battle Against Ovarian Cancer
• Predictive Oncology Reaches First Milestone in Building AI-driven Predictive Models of Ovarian Cancer

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) was highlighted today in a publication from Financialnewsmedia.com, examining how cannabis growth is expected to be incredibly explosive.  All thanks to incredible demand from consumers.  In the U.S. alone, 61% of Americans support the legalization of cannabis, according to the General Social Survey conducted by NORC at the University of Chicago.  That’s up from just 57% in 2016.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

• CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
• Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
• Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
• Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
• Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Wednesday's trading session at $3.70, up 7.2464%, on 2,565,711 volume with 8,409 trades. The average volume for the last 3 months is 1,348,255 and the stock's 52-week low/high is $2.71000003/$8.43999958.

Recent News

• Support for Cannabis Continues to Rise Among Consumers and Retailers
• 420 with CNW – Mexican Supreme Court Extends Marijuana Legalization Deadline
• First Hemp Processing Plant in Virginia Set to Be Launched

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) was featured today in the 420 with CNW by CannabisNewsWire. On Thursday, a Congressional committee approved legislation repealing the federal law that punishes college students who are ex-convicts of marijuana charges by denying or stripping them of their financial aid. The rule was enacted in 1998, by the Higher Education Act Aid Elimination Penalty. It has denied thousands of students’ access to means of paying tuition because of minor marijuana offenses.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Wednesday's trading session at $0.70, up 2.94%, on 38,000 volume with 10 trades. The average volume for the last 3 months is 93,233 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

• 420 with CNW – Congressional Committee Votes to Repeal Law Denying Students Aid Due to Drug Convictions
• Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) to Begin Trading on the OTCQB® Venture Market
• Petitioner Urges Iowa Cannabidiol Board to Add PTSD to Medical Marijuana Qualifying Conditions

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Sometimes what is gained on the roundabouts is lost on the swings, to paraphrase an old saying. Cannabis liberalization has introduced an entirely new sector to the food and beverage industry – namely, cannabis edibles such as cookies, chocolates and candies. It’s a sector that appears poised for growth. But as mass consumption increases, a hidden problem is emerging (http://cnw.fm/JwQv3). Because bioabsorption rates via edibles are slower than those via smoking, oral ingestion is leading to unexpected challenges. Consumers mistake the slow onset of effect of traditional cannabis edibles for not enough cannabinoid, so they increase consumption which can lead to overdosing. However, a biotech solution from Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appears to solve this problem. The company’s DehydraTECH(TM) drug-delivery platform greatly increases the rate at which drugs like cannabis are absorbed by the body. The technology could be used to avoid overdoses before they ever begin. Also today, the company was highlighted in a publication from CBDWire, examining how flying with marijuana has always been a tricky issue. Different states have different policies on marijuana, and what’s allowed in havens like California may not be allowed anywhere else.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.62, up 2.4963%, on 127,611 volume with 86 trades. The average volume for the last 3 months is 89,084 and the stock's 52-week low/high is $0.399800002/$1.70000004.

Recent News

• Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles
• Can You Fly With CBD? The Answer Will Surprise You!
• Lexaria Bioscience Appoints Gregg Smith as Senior Advisor Evolution VC Partners participates in equity financing

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media Corporation (TSXV: WNDR) (OTCQB: WDRFF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled “Entertainment Businesses Adopt New Approaches for Streaming Age,” visit: http://nnw.fm/YVur5

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

• SAW – $1.2 million budget = $103.9 million in sales
• Pulp Fiction – $8 million budget = $212 million in sales
• My Big Fat Greek Wedding – $5 million budget = $250 million in sales
• Lost in Translation – $4 million budget = $120 million in sales
• Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

• Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
• Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
• Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
• Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Wednesday's trading session at $0.1416, up 7.2727%, on 62,828 volume with 9 trades. The average volume for the last 3 months is 62,474 and the stock's 52-week low/high is $0.075099997/$0.504400014.

Recent News

• Wonderfilm Featured in Publication on Pivotal Moment in Streaming Services Timeline
• Wonderfilm Media Corp. (TSX.V: WNDR) (OTCQB: WDRFF) Producers Team Up to Tackle 2019 American Film Market
• Entertainment Businesses Adopt New Approaches for Streaming Age

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions, Inc. (OTCQB: SGSI) (the “Company” or “Spectrum”), a leading single-source provider of next-generation communications network infrastructure and maintenance solutions, today announced that it recently received over $2.5 million in new contract awards across all operating subsidiaries.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

• AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
• ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
• Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Wednesday's trading session at $0.026, even for the day, on 10,298 volume with 2 trades. The average volume for the last 3 months is 190,599 and the stock's 52-week low/high is $0.014999999/$0.800000011.

Recent News

• Spectrum Global Solutions Receives Over $2.5 Million in New Contract Awards
• Spectrum Global Solutions Inc. (SGSI) Anticipates Key Role in 5G Rollout, Provides Comprehensive Expertise and Services
• Spectrum Global Solutions Inc. (SGSI) Secures New Contract Awards Totaling More Than $3 Million

Dama Financial

The QualityStocks Daily Newsletter would like to spotlight Dama Financial.

Dama Financial this morning announced a new strategic partnership with PayWana(TM). Through the partnership, the company is integrating its PaytenderSM payment processing software and its online banking solution Dama Premier with PayWana self-service automated kiosk machines. PaytenderSM is an app-based consumer wallet that enables users to make electronic payments via QR “scan-and-go” technology. “The integration of PaytenderSM with Paywana self-ordering kiosks revolutionizes the retail checkout process, making it frictionless and automated. PayWana and PaytenderSM software represents the future of consumer checkouts and will no doubt become standard technology at quick service retailers,” Dama Financial CEO Dan Henry stated in the news release. To view the full press release, visit http://nnw.fm/gy9TP

Recent News

• Dama Financial Enters Strategic Partnership with PayWana
• Dama Financial Provides Access to Transparent Banking Services for Cannabis Industry
• Dama Financial is “One to Watch”

Green Hygienics Holdings Inc. (OTC: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings Inc. (OTCQB: GRYN), a full-scope, premium hemp cultivation and branding enterprise focused on the cultivation and processing of industrial hemp for the purpose of extracting cannabidiol (CBD), is well-positioned to take advantage of this booming sector of the economy. Fresh off a news release detailing the company’s acquisition of the 824-acre Potrero Ranch Property (http://cnw.fm/J6u3f), GRYN announced it has opened escrow for the acquisition of its head office and warehouse building in the prestigious Poway Business Park, both located near San Diego, California.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium hemp cultivation and branding enterprise focused on the cultivation and processing of industrial hemp for the purpose of extracting cannabidiol (CBD). With more than 25 years of experience in agricultural science and innovation, Green Hygienics aims to become one of the largest providers of industrial hemp-derived CBD products on the planet.

Green Hygienics’ business model includes generating revenues from the sale of hemp and premium-grade CBD products, creating trusted global consumer brands, developing valuable intellectual property (IP) and growing rapidly through strategic acquisitions. With direct regard to acquisitions, the company acts as a business accelerator and a vertical integrator supporting rapid growth and development of companies with extraordinary potential.

Innovation – the Future of Commercial Cultivation

The greatest challenge of the cannabis industry is determining how to deliver a safe and premium-quality product on a consistent basis; antiquated production methods are riddled with recalls and are unsafe from a cultivation production standpoint. Green Hygienics’ solution is to employ scientific methodology combined with sustainable farm practices to achieve optimal soil refinement. The company’s objectives are to produce higher yields and a superior product on a consistent basis to always remain compliant through diligent testing. A secure, premium-quality supply chain is the foundation for the company’s operations.

Green Hygienics’ cultivation approach is based on scientific measurements and data analysis, which transform the cultivation environment into a laboratory environment to deliver superior product.

State-of-the-Art Processing

Processing hemp to produce the finest-quality CBD is a complex, multistage process that should be performed with adherence to the highest standards. Once harvested, the hemp must be carefully handled, dried and stored to prepare it for CBD extraction. Each and every step must be given full care and attention. Green Hygienics’ ambition is to create state-of-the-art infrastructure, employ the latest large-scale processing technologies and adhere to strict quality management systems.

The company strives to constantly develop innovations in industrial hemp for CBD cultivation and to create solutions that lower costs, deliver higher yields and address the challenges of large-scale production.

Brand Development, Marketing and Direct Sales

One of the core drivers of the Green Hygienics business model is to develop or acquire unique brands with global distribution potential. The company sees the market becoming increasingly competitive, and establishing Green Hygienics’ own distinct, trusted brands will be important. By controlling its own supply chain, the company can also leverage strategic advantages in the marketplace, such as the ability to deliver a “best in class” product on a consistent basis. Successful branding is demonstrated by a positive response to a company’s customer service, reputation and products, and Green Hygienics Holdings is acutely aware of the value in this.

Ahead of the Curve

The clear competitive advantage Green Hygienics holds over industry peers is cultivating premium product within the upper-scale product category more efficiently than anyone else in the industry. Currently, the average-size hemp farm in North America is 9 acres. Green Hygienics addresses the challenge of scalability through its farming methodology.

The company’s objective is to produce a higher quality of product at a lower cost and to deliver the finest-quality product to consumers without exception.

In today’s market, inefficient companies and those that produce an inferior product will become vulnerable or disappear, adding considerable value to companies like Green Hygienics that efficiently innovate and operate. The premium cannabis market will continue to achieve higher pricing, and the demand will stabilize. At the end of the day, successful branding backed by superior product will cause companies like Green Hygienics to rise above the competition.

Outlook

Companies within the cannabis sector, states and lawmakers are still figuring out how legislation, consumer demand and innovations will shape the industry. As a safeguard and for long-term resilience, Green Hygienics is preparing for the next plateau with proprietary cultivation and processing systems and tightly controlled growth environments that enable containment of production costs, delivery of higher yields and production of a premium product. These margins will provide the company with a strategic advantage within an increasingly competitive marketplace.

Green Hygienics is constantly studying the market dynamics in North America and abroad and anticipates that both the domestic and international markets will appreciate and be willing to pay a premium to those companies that can deliver best-in-class products.

In line with this expectation, the company’s additional objectives are to secure investment, enhance its balance sheet and increase its value through profitable operations as well as through acquiring and owning the real estate or land it builds upon. Over the long term, this will help Green Hygienics grow in value, provide leverage for rapid expansion and offer security for investors. The company will be positioned to capitalize on any opportunity within the industry or to acquire distressed assets, which is part of its growth strategy.

Green Hygienics plans to establish lead brands starting in the California market, to secure trademarks, and to develop and secure intellectual property assets with regard to cultivation and processing.

Green Hygienics Holdings Inc. (GRYN), closed Wednesday's trading session at $1.90, off by 5.00%, on 5,595 volume with 11 trades. The average volume for the last 3 months is 20,778 and the stock's 52-week low/high is $0.100100003/$2.48000001.

Recent News

• Green Hygienics Holdings Inc. (GRYN) Pulls Ahead of the Curve in Hemp-Based CBD Market
• First Hemp Processing Plant in Virginia Set to Be Launched
• 420 with CNW – Marijuana Decriminalization Bill Filed in Wisconsin

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

People are starting to understand how vulnerable their data is and how big companies such as Facebook, Twitter, Snapchat and other social-media platforms track and sell that data. Every individual creates data by what they search, view, read, listen to, purchase and like. That data is collected and sold, generating billions in revenue each year. SRAX Inc. (NASDAQ: SRAX), through its BIGtoken platform, is placing power of that data back into an individual’s hands. Through SRAX, consumers can now own and monetize their personal data.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

• SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
• SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
• SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
• SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
• SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
• SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $1.58, off by 6.8726%, on 113,159 volume with 394 trades. The average volume for the last 3 months is 93,687 and the stock's 52-week low/high is $1.50999999/$5.8499999.

Recent News

• SRAX Inc. (NASDAQ: SRAX) Empowering Consumers to Profit from Personal Data, Protect Privacy
• SRAX Inc. (NASDAQ: SRAX) Ahead of Curve in New California Compliancy Law
• SRAX Inc. (NASDAQ: SRAX) Continues to Empower Customers in the Digital Wave of the Future: Consumer-Managed Data

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) was highlighted today in a publication from Motley Fool, examining how true to Halloween, October was another ghoulish month for cannabis stocks. After rocketing higher during the first quarter of the year, marijuana stocks have been in a precipitous seven-month downtrend. Last month, a majority of pure-play pot stocks ended the month lower, with the Horizons Marijuana Life Sciences ETF, the first exchange-traded fund focused on marijuana, losing another 12%. Since the end of March, this popular ETF has lost 50%, inclusive of dividends paid.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

• CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
• Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
• Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
• Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
• The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
• XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Wednesday's trading session at $1.16, off by 2.521%, on 166,086 volume with 190 trades. The average volume for the last 3 months is 232,290 and the stock's 52-week low/high is $0.843599975/$5.20499992.

Recent News

• The 9 Best Marijuana Stocks in October
• Parents of Epileptic Teen Plead For Easier Access to CBD Prescriptions
• CBD is Quickly Becoming the Most Searched Topic on Google

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, on Tuesday announced that it will be releasing its third quarter 2019 earnings after market close on Thursday, November 14, 2019. To register for the webcast, visit http://cnw.fm/J9sdh. To view the full press release, visit http://cnw.fm/3SZEf.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Wednesday's trading session at $0.771, off by 3.9851%, on 559,314 volume with 569 trades. The average volume for the last 3 months is 1,072,293 and the stock's 52-week low/high is $0.685999989/$4.38000011.

Recent News

• The Green Organic Dutchman Holdings to Release Third Quarter 2019 Earnings Results After Market Close on November 14, 2019
• Giant Breakthroughs with Psychedelics is Creating Incredible Investment Opportunities
• The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Building a Sustainable Business, From the Ground Up

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands, LP (VPRB) was featured today in a publication from CBDWire, examining how flying with marijuana has always been a tricky issue. Different states have different policies on marijuana, and what’s allowed in havens like California may not be allowed anywhere else.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

• GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit www.cbdgoldline.com.
• HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit www.vapehoneystick.com.
• Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
• Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
• Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
• GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit www.goldlinehemp.com for more information about GoldLine Hemp-only products.
• Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Wednesday's trading session at $0.038, off by 15.5556%, on 51,000 volume with 3 trades. The average volume for the last 3 months is 136,690 and the stock's 52-week low/high is $0.033799998/$0.119999997.

Recent News

• Can You Fly With CBD? The Answer Will Surprise You!
• VPR Brands LP (VPRB) CEO Commissions Presidential Candidate Study Regarding Cannabis Issues
• Cannabis and Hemp Jobs Expand Despite Regulatory Uncertainties

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) was recently featured in a Wect.com article by Jack Bailey titled, ‘Medical device lowers opioid prescriptions at NHRMC’. To view the full press release, visit http://nnw.fm/Mat52.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Wednesday's trading session at $0.0053, off by 3.6364%, on 4,513,852 volume with 65 trades. The average volume for the last 3 months is 4,745,446 and the stock's 52-week low/high is $0.0035/$0.043000001.

Recent News

• Endonovo Therapeutics Inc.’s (ENDV) SofPulse(R) Reduces Opioid Prescriptions at New Hanover Regional Medical Center
• Endonovo Therapeutics Inc. (ENDV) Names Strategic Advisor to CEO
• NetworkNewsBreaks Covers Endonovo Therapeutics Inc. (ENDV) Reverse Stock Split

LiveWire Ergogenics Inc. (OTC: LVVV)

The QualityStocks Daily Newsletter would like to spotlight LiveWire Ergogenics Inc. (LVVV).

LiveWire Ergogenics Inc. (OTC: LVVV) was featured today in a publication from HempWireNews, examining how the USDA started accepting public comments on hemp production regulations. The process which will be carried out the whole month of December presents the citizens with an opportunity to voice their opinions regarding the interim final rule that was released on Tuesday by the Department of Agriculture.

LiveWire Ergogenics Inc. (OTC: LVVV) is a forward-thinking company specializing in identifying and monetizing current and future trends in the health and wellness industry. The company recognizes significant potential in the multibillion-dollar cannabis industry and operates at the forefront for acquisition and management of licensed cannabis real estate locations and the research, development and commercialization of high-end products for distribution throughout California.

During the past two years, LiveWire has diligently researched, secured, designed and set up several fully compliant and permitted cannabis operations in locations in California, including a state-wide distribution license from the Bureau of Cannabis Control. The company is focused on acquiring compliant real estate properties for cannabis operations and entering into operation agreements and strategic alliances to build teams of carefully selected and vetted operators, horticulturists, extractors, distributors and establish research partnerships. Its current portfolio of cannabis operations consists of the following properties:

PODs and Distribution in Coachella, California

For the past year, LiveWire has operated high-tech, state-of-the-art production structures, or “PODs” for its cannabis nursery business. Coachella is also home to the company’s statewide distribution headquarters. Both entities operate under LiveWire’s majority owned subsidiary, GHC Ventures. The company is currently in the process to strategically centralize all operations at its recently acquired Paso Robles facility, Estrella Ranch.

Estrella Ranch in Paso Robles, California

Through its subsidiary, Estrella Ranch Partners LLC, LiveWire acquired a 265-acre historic ranch property in Paso Robles, Calif. Estrella Ranch has a longstanding history, once owned by George R. Hearst, the eldest grandson of the late William Randolph Hearst, developer of Hearst Communications, and is considered among the finest ranches in California and the gem of the California Central Coast. LiveWire is transforming this property into the world’s first “Estate-Grown Weedery” with plans to develop it into a vertically integrated, high-end cannabis facility and wellness retreat in California. The stunning property, located in the heart of the world renown California wine country, currently houses three spacious residences, storage areas, and elaborate equestrian facilities with four barns and numerous stables. LiveWire is designing a truly unique property that features indoor and outdoor cannabis operations, including large outdoor and indoor cannabis production. Long-range plans include adding teaching and luxury recreational facilities focused on providing a comprehensive and unique cannabis-related retreat experience.

The Paso Robles Nursery

LiveWire has begun the build-out and will soon begin production in its 22,000-square-foot secure indoor cannabis nursery facility in Paso Robles, Calif. The project includes the conversion of two existing buildings with sufficient power capacity and abundant water supply. Floor plans include more than 10,000 square feet of canopy devoted to “mother” plants and separate clone storage; additional space has been identified for flowering plants. Within the two buildings, the nursery also contains research and development areas, rooms for cannabis waste and storage, record keeping and staging space, security offices, a conference room and additional designated locations required for permit approval and compliance.

LiveWire has spent significant resources to research and maneuver a complex legal environment and confirm the economic and environmental feasibility of potential LiveWire cannabis operations in different locations throughout the state of California. All LiveWire operations comply with California state law and local ordinances. To fully capitalize on these highly valuable assets, LiveWire is seeking funding to accelerate the development of its business plan.

GHC Ventures Subsidiary

GHC Ventures, LiveWire’s Coachella-based distribution division, employs a consumer-driven market approach that provides retailers access to a wide range of new high-end cannabis products, all serviced through the licensed and reliable GHC supply chain and distribution network.

GHC Ventures’ distribution network is available exclusively to licensed manufacturers that pass LiveWire’s stringent legal and environmental qualification process. This enables LiveWire to provide a large and solidly structured legal distribution network for all qualifying third-party operators in California. LiveWire is actively seeking to work with licensed operators who are enthusiastic and qualified to ensure the delivery of high-caliber and legal cannabis products for the fast-growing California medical and recreational cannabis markets.

Research Partnerships

LiveWire has established two independent research teams with world-renowned experts in their respective fields to pursue application of cannabis derivatives to specific targeted medical ailments. The company is also establishing research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with large “sufferer” populations for both human and veterinarian applications. Possible applications may include dosing verification of zero-pesticide products for quality brands via its 7X Pure Cannabis Dosing and Verification System.

LiveWire has also engaged a highly qualified research team and advisory board to explore the opportunities in the unexplored yet highly valued equine space. The company has entered into consulting and/or advisory board agreements with high-caliber individuals from the medical and international-performance equine sector and is currently exploring strategic relationships with the veterinary departments of leading local and domestic universities and medical facilities.

7X Pure™ Dosing and Verification System

LiveWire Ergogenics is developing its “7X Pure Compliance and Dosage Verification System” intended to provide third-party verification of cannabis material origin, potency, purity, dosage and labeling, securing each product with a digital identity and clearly identifiable chain of custody.

The 7X Pure system will be completely secure, transparent and verifiable, protecting the confidentiality of growers’ and manufacturers’ intellectual property while providing retailers, consumers, government officials and others verification that the growers’ and manufacturers’ claims are true.

The system is designed as a parallel service to the seed-to-sale data provided by marijuana tracking software, will help growers and manufacturers meet increasing compliance requirements related to logistics, quality and transparency. It will also provide a high level of assurance to everyone from end users to municipalities.

Acquisitions & Operations

To maximize the utilization of its fully compliant locations and the licenses granted throughout California, LiveWire has begun and continues to pursue acquisitions of and/or strategic alliances with qualified cannabis companies and consultants. LiveWire will apply a strict regimen to the acquisition of operators, carefully utilizing its experience and legal standing in the California cannabis market for the selection of qualified operators.

Market Opportunity

Legal marijuana is the fastest-growing industry in the United States. Twenty-nine states have already legalized medical marijuana, eight states have approved it for recreational use, and more are following suit. Once the trend toward legalization expands to all 50 states, marijuana could become larger than the organic food industry, according to a new report obtained by The Huffington Post.

The U.S. marijuana industry is forecast to generate annual revenues ranging from $17 billion to $35 billion by 2021. The combined legal medical and recreational market has grown by roughly 30 percent, reaching $6 billion during 2017, according to The Marijuana Business Factbook. The same study projects the market will increase 300 percent to top $17 billion by 2021. During 2017 recreational sales grew by 80 percent, reaching $1.8 billion, not yet accounting for sales of the biggest revenue producer, California, which will only commence with recreational sales in 2018.

Business Model

LiveWire’s diligent approach to the cannabis sector is based on extensive environmental and legal research to predetermine the feasibility of the locations it selects for operations. The company pursues a carefully selected approach of acquiring, licensing and managing self-contained and permitted real estate properties for the development and distribution of its products and leasing to third party operators. LiveWire avoids the complications and high start-up cost of the typical large “growing” operations, instead focusing on becoming the market leader in research, cloning and verification, producing and distributing high quality brands.

Management Team

LiveWire’s team of experienced corporate managers and innovators are leading the company’s plans to capture increasing market share from different and often underserved market sectors in the cannabis industry. LiveWire intends to utilize its team’s experience to accelerate the development and/or acquisition of new properties, product offerings, and companies.

Bill Hodson, CEO & Chairman of the Board
Bill Hodson is responsible for the strategic direction of the firm’s development, branding, sales and marketing strategies. In addition to being responsible for the operation of the company, he leads the development and manages implementation of the company’s innovative product strategy. Previously the executive vice president of LiveWire Sports Group, Hodson was responsible for overseeing all LiveWire’s operations, including the launch of several sports publications and one of the country’s largest sports consumer expos.

As early as five years ago, Hodson recognized the potential of CBD and became an early adopter of CBD as a health and wellness supplement by including hemp-derived cannabidiol in a starburst size edible product. His experience includes not only product development, marketing and sales, but most significantly constant city and county advocacy, guiding the company through four license processes, identifying and spearheading real estate acquisitions, and to assemble operations teams comprised of nursery horticulturists, cultivators and distribution personnel. His vision for the industry is complimented with his out-of-the-box thinking and anticipation of positioning for the future.

Kyle McKay, Horticulturist
Kyle McKay is responsible for managing LiveWire’s controlled cultivation environment, developing new-age genetics to produce consistent and high-quality products for medical patients, and applying his expertise in integrated pest management with Omri-certified fungicides and pesticides. McKay oversees the company’s clone development and supervises both cultivation facilities in Coachella and Paso Robles. He also assists with location research and selection; cultivation center planning; operations set-up; and maximizing the growth potential of cannabis edibles, concentrates and oil production. McKay’s expertise in plant genetics and modern horticulture technology makes him extremely qualified to guide LiveWire’s efforts. During his 12-plus years in the cannabis horticulture field, he has grown more than 230 stable genetics, managed over 27 cultivation centers and grown the specific strains required to meet the needs of up to 45,000 medical cannabis patients at one time.

Advisory Board

Jeff Halloran, Investment Banker
Jeff Halloran is an accomplished senior-management executive with more than 35 years of experience. He has founded and held top positions in large financial and technology firms and has an outstanding record of achievement managing multimillion and billion-dollar programs. Halloran will use his standing in the Canadian markets to provide LiveWire with research and advice for potential acquisitions and strategic alliance targets in the burgeoning Canadian cannabis markets. Halloran has spent most of his career in leading management and consulting positions gathering extensive knowledge in strategic business analysis and information management theories. He served as managing director of Avalon Capital and Halloran Investment, as well as chairman and/or CEO of several companies owned by MT Dynamics. As a consulting manager he was recruited by Oracle Corporation to establish the multibillion-dollar organization’s consulting practice in Canada, eventually earning a place on the design team for Oracle Financials and its CASE Tool and Methodology. Halloran also heads up the executive committee for the Willow Breast Cancer Support Organization.

Michael Corrigan, Attorney at Law
Michael Corrigan is a legal professional at the Law Offices of Michael L. Corrigan, practicing in San Diego, Calif. His practice emphasizes general and SEC representation of emerging high-technology and other operating companies. He has been counsel to private and public companies in a broad range of industries, including computer hardware and software, telecommunications, multimedia and cannabis.

Matthew Geriak, Clinical Pharmacist and Investigational Research Pharmacist
Matthew Geriak is a specialized pharmacist and has a system-wide position on the Investigational Review Board for Sharp Healthcare, which owns five hospitals and various clinics throughout San Diego County. Sharp conducts drug research spanning from phase 1 to 4 human research clinical trials focusing on the fields of oncology, renal and heart transplantations, septic shock treatment, infectious diseases and anticoagulation. Geriak is the primary investigator for retrospective cohorts in the field of infectious diseases.

Jimmy Connors, Sports Industry Adviser
Jimmy Connors is a legendary No. 1 ranked tennis player and is considered among the greatest in the history of the sport. Today, Connors still holds three prominent Open Era Men’s singles records: 109 titles, 1,535 matches played, and 1,256 matches won. His titles include eight?majors, five U.S. Opens, two Wimbledons, one Australian Open, three year-end championships and 17?Grand Prix Super Series. Connors brings a wealth of knowledge in the sports and wellness industries that will be especially important as LiveWire expands into its next phase of development with its topical products. His decade-long exposure in the global sports world as one of the most recognized personalities adds a high level of exposure and supports LiveWire’s efforts to set itself apart in a fast-growing and still turbulent and disruptive industry.

LiveWire Ergogenics Inc. (OTC: LVVV), closed Wednesday's trading session at $0.005, off by 5.6604%, on 544,835 volume with 26 trades. The average volume for the last 3 months is 1,095,576 and the stock's 52-week low/high is $0.004199999/$0.0405.

Recent News

• USDA Starts Accepting Public Comments on Hemp Production Rules
• Ontario University to Study Cannabidiol as a Dog Cancer Treatment
• LiveWire Ergogenics Inc. (LVVV) Takes Cues from Prohibition Era to Optimize Business Model